This site is intended for US Healthcare Professionals only.

Treatment-Naïve Patients

A treatment with durable efficacy in treatment-naïve patients

ELZONRIS is the first and only approved treatment for BPDCN, a deadly hematologic cancer.1,2

Efficacy in treatment-naïve patients (N=29)3*

72%

CR/CRc rate†

90%

ORR

45%

bridged to stem cell transplantation

  • The median duration of CR/CRc has not yet been reached; median follow-up 19 months (range, 1-42 months)3
  • The median time to CR/CRc was 43 days (range, 14-131 days)3
  • The median time from the first dose to stem cell transplantation (SCT) was 4.4 months (range, 76-203 days)4

Efficacy in the pivotal cohort (N=13)1,4

54%

CR/CRc rate†

77%

ORR

46%

bridged to stem cell transplantation

  • The median duration of CR/CRc has not yet been reached (range, 3.9-12.2 months)1
  • The median time to CR/CRc was 57 days (range, 14-107 days)1

In other cohorts (N=16)4

  • Efficacy measures included 88% CR/CRc rate,† 100% ORR, and 44% bridged to stem cell transplantation4
  • The median duration of CR/CRc has not yet been reached (range, 1.3-32.2 months)4

*All-cohorts population includes patients from the pivotal cohort.

†CRc = clinical complete response; defined as complete response with residual skin abnormality not indicative of active disease.1

BPDCN = blastic plasmacytoid dendritic cell neoplasm; CR = complete response; ORR = overall response rate.

Explore the baseline characteristics of treatment-naïve patients in the study

Key baseline demographics in the study reflect the patient population and variable presentation of BPDCN.1,4

Baseline characteristics: Treatment-naïve patients1,4

Characteristics Pivotal cohort
(n=13)		 Other cohorts
(n=16)		 All cohorts
(n=29)
Male, % (n) 84.6% (11) 75.0% (12) 79.3% (23)
Female, % (n) 15.4% (2) 25.0% (4) 20.7% (6)
Median age
(min, max)		 65.0 (22, 84) 67.5 (28, 84) 67.0 (22, 84)
ECOG PS, % (n)
0 61.5% (8) 43.8% (7) 51.7% (15)
1 38.5% (5) 56.3% (9) 48.3% (14)
BPDCN, % (n)
Skin 100.0% (13) 93.8% (15) 96.6% (28)
Bone marrow 53.8% (7) 43.8% (7) 48.3% (14)
Peripheral blood 23.1% (3) 25.0% (4) 24.1% (7)
Lymph nodes 46.2% (6) 43.8% (7) 44.8% (13)
Viscera 15.4% (2) 12.5% (2) 13.8% (4)

ECOG PS = Eastern Cooperative Oncology Group performance status.

Overall survival in treatment-naïve patients

Median overall survival not yet reached (n=29; 12 mcg/kg)3

Median Overall Survival in BPDCN Study Median Overall Survival in BPDCN Study

Cutoff: October 2018.

  • Median overall survival (OS) not yet reached; median follow-up 25 months3
Discover meaningful efficacy in previously-treated patients
  1. References:
  2. ELZONRIS [prescribing information]. New York, NY, US: Stemline Therapeutics, Inc.; December 2018.
  3. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
  4. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
  5. Data on file. Stemline Therapeutics, Inc.

INDICATION

  • ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

  • Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

  • ELZONRIS can cause capillary leak syndrome (CLS), which may be life-threatening or fatal if not properly managed. The overall incidence of CLS in clinical trials was 55% in patients receiving ELZONRIS, including 46% in Grades 1 or 2, 6% in Grade 3, 1% in Grade 4, and 2 fatal events. Common signs and symptoms (incidence ≥ 20%) associated with CLS that were reported during treatment with ELZONRIS include hypoalbuminemia, edema, weight gain, and hypotension
  • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is ≥ 3.2 g/dL
  • During treatment with ELZONRIS, ensure that serum albumin levels are ≥ 3.5 g/dL and have not been reduced by ≥ 0.5 g/dL from the albumin value measured prior to dosing initiation of the current cycle. Monitor serum albumin levels prior to the initiation of each dose or more often as indicated clinically thereafter. Additionally, assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema including pulmonary edema, hypotension, or hemodynamic instability
  • Counsel patients to seek immediate medical attention should signs or symptoms of CLS occur at any time

Hypersensitivity Reactions

  • ELZONRIS can cause severe hypersensitivity reactions. Grade 3 or higher events were reported in 10% of patients in clinical trials. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur. If the reaction is severe, discontinue ELZONRIS permanently

Hepatotoxicity

  • Elevations in liver enzymes can occur with ELZONRIS. Grade 3 or higher elevations in liver enzymes occurred in approximately 40% of patients in clinical trials
  • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Temporarily withhold ELZONRIS if the transaminases rise to greater than 5 times the upper limit of normal (ULN) and resume treatment upon normalization or when resolved

ADVERSE REACTIONS:

The most common adverse reactions in the clinical trials (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose, ALT, and AST.

Please see full Prescribing Information, including Boxed WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION

INDICATION

  • ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

  • Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

  • ELZONRIS can cause capillary leak syndrome (CLS), which may be life-threatening or fatal if not properly managed. The overall incidence of CLS in clinical trials was 55% in patients receiving ELZONRIS, including 46% in Grades 1 or 2, 6% in Grade 3, 1% in Grade 4, and 2 fatal events. Common signs and symptoms (incidence ≥ 20%) associated with CLS that were reported during treatment with ELZONRIS include hypoalbuminemia, edema, weight gain, and hypotension
  • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is ≥ 3.2 g/dL
  • During treatment with ELZONRIS, ensure that serum albumin levels are ≥ 3.5 g/dL and have not been reduced by ≥ 0.5 g/dL from the albumin value measured prior to dosing initiation of the current cycle. Monitor serum albumin levels prior to the initiation of each dose or more often as indicated clinically thereafter. Additionally, assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema including pulmonary edema, hypotension, or hemodynamic instability
  • Counsel patients to seek immediate medical attention should signs or symptoms of CLS occur at any time

Hypersensitivity Reactions

  • ELZONRIS can cause severe hypersensitivity reactions. Grade 3 or higher events were reported in 10% of patients in clinical trials. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur. If the reaction is severe, discontinue ELZONRIS permanently

Hepatotoxicity

  • Elevations in liver enzymes can occur with ELZONRIS. Grade 3 or higher elevations in liver enzymes occurred in approximately 40% of patients in clinical trials
  • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Temporarily withhold ELZONRIS if the transaminases rise to greater than 5 times the upper limit of normal (ULN) and resume treatment upon normalization or when resolved

ADVERSE REACTIONS:

The most common adverse reactions in the clinical trials (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose, ALT, and AST.

Please see full Prescribing Information, including Boxed WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.